Targeting Cdc20 as a novel cancer therapeutic strategy

Area of Science:

• Cell Biology
• Molecular Oncology

Background:

• The Anaphase Promoting Complex (APC/C) is crucial for cell cycle regulation.
• APC/C forms two distinct sub-complexes, APC(Cdc20) and APC(Cdh1), with opposing roles in tumorigenesis.
• Cdh1 acts as a tumor suppressor, while Cdc20 exhibits oncogenic functions.

Purpose of the Study:

• To explore the molecular mechanisms behind Cdc20 and Cdh1's opposing roles in tumorigenesis.
• To summarize Cdc20's substrates, functions, upstream regulators, and oncogenic roles.
• To review potential Cdc20 inhibitors for cancer therapy.

Main Methods:

• Literature review of downstream substrates of Cdc20.
• Summary of Cdc20's functions in cell cycle, apoptosis, ciliary disassembly, and brain development.
• Analysis of Cdc20's upstream regulators and oncogenic roles in various cancers.

Main Results:

• Cdc20 has critical functions in cell cycle progression, apoptosis, ciliary disassembly, and brain development.
• Cdc20 plays an oncogenic role in various human malignancies.
• Pharmacological inhibitors of Cdc20, such as TAME and Apcin, show potential clinical benefits.

Conclusions:

• Understanding Cdc20's molecular mechanisms is key to developing targeted cancer therapies.
• Targeting Cdc20, which has an oncogenic function, presents a novel therapeutic strategy for cancers with elevated Cdc20 expression.
• Development of specific Cdc20 inhibitors could offer significant clinical benefits for cancer treatment.